has function has role vaccinated in route immunizes against disease immunizes recipient ovarian cancer Homo sapiens subunit vaccine therapeutic vaccine function subunit vaccine role vaccine in clinical trial role intradermal route ovarian cancer vaccine autologous oxidized ovarian tumor cell lysate vaccine NCT: [https://clinicaltrials.gov/study/NCT01312376 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6330 Hayleigh Kahn A cancer vaccine that is composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. The autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response. Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer may help treat their tumors. Patients will receive 5-10 million cells intradermally. NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C122402 Jie Zheng cancer vaccine 6330 therapeutic cancer vaccine